Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glaxo antibacterial treatment approved by FDA
The drug is indicated for impertigo caused by susceptible strains of staphylococcus aureus or streptococcus pyogenes, the two most common types of bacteria in this kind of infection,
The drug is indicated for impertigo caused by susceptible strains of staphylococcus aureus or streptococcus pyogenes, the two most common types of bacteria in this kind of infection,
The study met its primary endpoint of increasing recurrence-free survival. However, there was no difference in overall survival for patients on the two treatment arms. Researchers found that
The committee said it voted against recommending the drug Arcoxia, for the treatment of osteoarthritis, because data suggests the drug is no more effective than similar drugs in
The company previously announced that it had filed an investigational new drug application with the FDA for an oral formulation of picoplatin in February 2007. The phase I
According to these analyses, Mircera corrected and maintained hemoglobin (Hb) levels in patients with chronic kidney disease (CKD). The drug also maintained Hb levels in dialysis patients, regardless
The drug produced disappointing results in one study but in another ongoing a study the data was more encouraging. One study showed that when valopicitabine was combined with
DX-88, an internally discovered, recombinant, plasma kallikrein inhibitor, is in clinical trials for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disease characterized by
Schiff Nutrition said sales were $45 million for the third quarter of fiscal 2007, compared to the $49.6 million recorded in the same period in fiscal 2006. Bruce
The antihistamine previously made the switch from the prescription to the over-the-counter market. The Division of Bioequivalence has determined Ranbaxy’s loratadine orally disintegrating tablets, 10mg, to be bioequivalent
The first patient has been dosed in the first phase IIa trial, which is designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profile of an intravenous formulation